Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 25, 2017
What is the competitive landscape for TAKEDA PHARMS USA, and when can generic versions of TAKEDA PHARMS USA drugs launch?
TAKEDA PHARMS USA has seventeen approved drugs.| Patents: | 82 |
| Tradenames: | 17 |
| Ingredients: | 14 |
| NDAs: | 17 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
alogliptin and metformin hydrochloride | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | KAZANO | 1/25/2017 |
alogliptin | Tablets | 6.25 mg, 12.5 mg and 25 mg | NESINA | 1/25/2017 |
febuxostat | Tablets | 40 mg and 80 mg | ULORIC | 2/13/2013 |
colchicine | Tablets | 0.6 mg | COLCRYS | 12/23/2011 |
pioglitazone hydrochloride and metformin hydrochloride | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ACTOPLUS MET XR | 9/23/2011 |
dexlansoprazole | Delayed-release Capsule | 30 mg | DEXILANT | 11/30/2010 |
dexlansoprazole | Capsule | 60 mg | DEXILANT | 8/25/2010 |
pioglitazone hydrochloride and glimepiride | Tablets | 30 mg/2 mg and 30 mg/4 mg | DUETACT | 12/22/2009 |
ramelteon | Tablets | 8 mg | ROZEREM | 7/22/2009 |
pioglitazone hydrochloride and metformin hydrochloride | Tablets | 15 mg/500 mg and 15 mg/850 mg | ACTOPLUS MET | 3/6/2008 |
lansoprazole | Delayed-release Orally Disinte | 15 mg and 30 mg | PREVACID | 12/27/2006 |
lansoprazole | Delayed-release Pellets/Capsul | 15 mg and 30 mg | PREVACID | 12/5/2005 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,110,567 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | ► Subscribe | |||||||||||||
| 7,683,053 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | ► Subscribe | |||||||||||||
| 7,148,238 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | ► Subscribe | |||||||||||||
| 7,138,407 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | ► Subscribe | |||||||||||||
| 7,157,429 | Method of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| 7,829,530 | Method of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| 6,803,357 | Method of regulating glucose metabolism, and reagents related thereto | ► Subscribe | |||||||||||||
| 9,101,626 | Process for preparing 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or pharmaceutically acceptable salt thereof | ► Subscribe | |||||||||||||
| 7,795,428 | Dipeptidyl peptidase inhibitors | ► Subscribe | |||||||||||||
| 6,288,090 | Pharmaceutical composition | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eurasian Patent Organization | 017058 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 03029232 | ► Subscribe | |||||||||||||
| Argentina | 054238 | ► Subscribe | |||||||||||||
| New Zealand | 552592 | ► Subscribe | |||||||||||||
| Slovakia | 283970 | ► Subscribe | |||||||||||||
| Canada | 2338792 | ► Subscribe | |||||||||||||
| Colombia | 5700740 | ► Subscribe | |||||||||||||
| China | 1713897 | ► Subscribe | |||||||||||||
| Taiwan | 201129553 | ► Subscribe | |||||||||||||
| Spain | 2328308 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 5006-2014 | Slovakia | ► Subscribe | PRODUCT NAME: ALOGLIPTIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/13/844/001 - EU/1/13/844/027 20130923 | ||||||||||||
| 334 | Luxembourg | ► Subscribe | CERTIFICATE TITLE: SITAGLIPTIN, OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER LE SEL PHOSPHATE (JANUVIA); FIRST REGISTRATION: 20070321 | ||||||||||||
| 2014 00066 | Denmark | ► Subscribe | PRODUCT NAME: ALOGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER ALOGLIPTIN BENZOATE; REG. NO/DATE: EU/1/13/844/001-027 20130919 | ||||||||||||
| 14/012 | Ireland | ► Subscribe | PRODUCT NAME: ALOGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/844/001-027 20130919 | ||||||||||||
| 00706 | Netherlands | ► Subscribe | PRODUCT NAME: VILDAGLIPTINE; REGISTRATION NO/DATE: EU/1/07/414/001-017 20070926 | ||||||||||||
| C/GB10/019 | United Kingdom | ► Subscribe | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/019 GRANTED TO TEIJIN LIMITED IN RESPECT OF THE PRODUCT FEBUXOSTAT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6408 DATED 14/03/2012 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22/04/2023. | ||||||||||||
| /2010 | Austria | ► Subscribe | PRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421 | ||||||||||||
| 2014011 | Lithuania | ► Subscribe | PRODUCT NAME: ALOGLIPTINUM; REGISTRATION NO/DATE: EU/1/13/844 20130919 | ||||||||||||
| 0140037 00152 | Estonia | ► Subscribe | PRODUCT NAME: FEBUKSOSTAAT;REG NO/DATE: EU/1/08/447 23.04.2008 | ||||||||||||
| 00640 | Netherlands | ► Subscribe | PRODUCT NAME: ALOGLIPTINE IN ALLE VORMEN ZOALS BESCHERMD DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/13/844/001-007 20130923 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,766 others who get our Drug Patent Expiration Alerts:
